Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY57LN
|
|||
| Drug Name |
Cevidoplenib
|
|||
| Synonyms |
Cevidoplenib; Cevidoplenib [INN]; 1703788-21-9; 3N3H8BX897; UNII-3N3H8BX897; Methanone, cyclopropyl(5-((4-(4-(((4S)-4-hydroxy-2-isoxazolidinyl)methyl)-3-methyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-1-methyl-1H-indol-3-yl)-; cyclopropyl-[5-[[4-[4-[[(4S)-4-hydroxy-1,2-oxazolidin-2-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1-methylindol-3-yl]methanone; Cevidoplenib [WHO-DD]; CHEMBL3921923; SCHEMBL16653204; YCZUBLQESBVOSH-IBGZPJMESA-N; BDBM196772; EX-A5914; AKOS040748110; MS-28778; HY-109082; CS-0039259; US9212178, 1; (S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 2 | [1] | |
| Company |
Genosco
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H27N7O3
|
|||
| Canonical SMILES |
CC1=NN(C=C1CN2CC(CO2)O)C3=NC(=NC=C3)NC4=CC5=C(C=C4)N(C=C5C(=O)C6CC6)C
|
|||
| InChI |
InChI=1S/C25H27N7O3/c1-15-17(10-31-12-19(33)14-35-31)11-32(29-15)23-7-8-26-25(28-23)27-18-5-6-22-20(9-18)21(13-30(22)2)24(34)16-3-4-16/h5-9,11,13,16,19,33H,3-4,10,12,14H2,1-2H3,(H,26,27,28)/t19-/m0/s1
|
|||
| InChIKey |
YCZUBLQESBVOSH-IBGZPJMESA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Genosco | |||
| REF 2 | A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.